Burkholderia cepacia complex: Difference between revisions

Revision as of 12:42, 6 February 2023

Gram-negative bacillus
Classified into nine genomovars (phenotypically similar but genotypically distinct)
- Burkholderia cenocepacia (genomovar III)
- Burkholderia multivorans (genomovar II)
- Burkholderia dolosa (genomovar VI)
Multiple mechanisms of resistance:
- β-lactamases
- RND efflux pumps
- Altered LPS conferring polymixin resistance
- Gyrase mutations conferring fluoroquinolone resistance

Opportunistic lung infections, primarily of cystic fibrosis and lung transplant patients
Colonizes the lungs of patients with cystic fibrosis and portends a poor prognosis

Should be guided by antimicrobial susceptibility testing
Antibiotic options include:
- TMP-SMX (preferred, if susceptible)
- Ceftazidime and ceftazidime-avibactam
- Meropenem and imipenem
- Minocycline

@@ Line 2: / Line 2: @@
 * [[Stain::Gram-negative]] [[Shape::bacillus]]
+* Classified into nine genomovars (phenotypically similar but genotypically distinct)
+** [[Burkholderia cenocepacia]] (genomovar III)
+** [[Burkholderia multivorans]] (genomovar II)
+** [[Burkholderia dolosa]] (genomovar VI)
 * Multiple mechanisms of resistance:
 ** β-lactamases
@@ Line 7: / Line 11: @@
 ** Altered LPS conferring polymixin resistance
 ** Gyrase mutations conferring fluoroquinolone resistance
+== Clinical Manifestations ==
+* Opportunistic lung infections, primarily of [[cystic fibrosis]] and [[lung transplant]] patients
+* Colonizes the lungs of patients with [[cystic fibrosis]] and portends a poor prognosis
 == Management ==